Check-Cap to merge with MBody AI in embodied AI workforce push
Investing.com - Stifel has reiterated a Buy rating on Kestra Medical Technologies (NASDAQ:KMTS) while maintaining its $28.00 price target following the company’s strong fiscal first quarter results. According to InvestingPro data, the stock has gained over 8% in the past week, with analyst targets ranging from $20 to $30.
Kestra Medical Technologies reported first quarter sales of $19.4 million, representing 52% year-over-year growth and exceeding both Stifel’s and Wall Street’s expectations of approximately $17.8-17.9 million. The company maintains strong financial health with a current ratio of 6.72 and holds more cash than debt on its balance sheet.
The medical device company’s ASSURE wearable cardioverter-defibrillator vest showed prescription growth of approximately 51% in the quarter, significantly outpacing Stifel’s estimate of 39%.
Kestra has implemented several growth initiatives, including U.S. sales territory expansion, increased in-network patient mix, and new hospital account openings, which contributed to the quarterly performance.
The company’s strong performance was attributed to its expanding sales force successfully deepening relationships with existing accounts while opening new ones, with additional benefit coming from a higher in-network patient mix.
In other recent news, Kestra Medical Technologies reported a significant 52% increase in revenue for the first quarter of fiscal year 2026, totaling $19.4 million. Despite this impressive revenue growth, the company experienced a net loss, with earnings per share at -0.5 USD. Investors responded positively to the revenue performance, and the company also raised its guidance for the full year. These developments are part of the recent updates surrounding Kestra Medical. The company’s financial performance is drawing attention, particularly with the raised guidance offering insights into future expectations. Analysts and investors are closely monitoring these figures as they provide a clearer picture of the company’s trajectory. The focus remains on how Kestra Medical plans to leverage its revenue growth while addressing its net loss.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.